tradingkey.logo

scPharmaceuticals Inc <SCPH.OQ> expected to post a loss of 30 cents a share - Earnings Preview

ReutersMay 12, 2025 8:29 PM
  • scPharmaceuticals Inc SCPH.OQ SCPH.O is expected to show a rise in quarterly revenue when it reports results on May 14 for the period ending March 31 2025

  • The Burlington Massachusetts-based company is expected to report a 90.6% increase in revenue to $11.628 million from $6.1 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for scPharmaceuticals Inc is for a loss of 30 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for scPharmaceuticals Inc is $12.50​, above​ its last closing price of $2.44. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.44

-0.38

-0.35

Beat

7.5

Sep. 30 2024

-0.29

-0.30

-0.75

Missed

-153

Jun. 30 2024

-0.42

-0.41

-0.44

Missed

-6.3​

Mar. 31 2024

-0.44

-0.44

-0.36

Beat

17.6

​​Dec. 31 2023

-0.52

-0.42

-0.35

Beat

16.4

Sep. 30 2023

-0.37

-0.36

-0.41

Missed

-12.4​

Jun. 30 2023

-0.37

-0.37

-0.36

Beat

3.3

Mar. 31 2023

-0.39

-0.36

-0.30

Beat

17.8

This summary was machine generated May 12 at 20:29 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI